alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE> 1




                              NEW YORK BANCORP INC.
                            241-02 Northern Boulevard
                           Douglaston, New York 11362


                                    Form 10-Q
                                 March 31, 1997


Exhibit 11.  Statement re:  Computation of Per Share Earnings (Loss)

<TABLE>
<CAPTION>
                                                  Three Months Ended   Six Months Ended
                                                       March 31,           March 31,
                                                 --------------------  -----------------
                                                   1997      1996(1)    1997     1996(1)
                                                 --------   ---------  -------  --------
                                                 (In Thousands, except per share amounts)


<S>                                               <C>        <C>       <C>       <C>    
Net income......................................  $13,913    $ 9,176   $24,177   $17,004
                                                  =======    =======   =======   =======

Weighted average common shares outstanding......   16,569     17,815    16,597    17,865

Common stock equivalents due to dilutive
 effect of stock options........................      628        381       625       400
                                                  -------    -------   -------   -------

Total weighted average common shares and
 equivalents outstanding........................   17,197     18,196    17,222    18,265
                                                  =======    =======   =======   =======

Primary earnings per share......................    $ .81     $  .50    $ 1.40     $ .93
                                                  =======    =======   =======   =======

Total weighted average common shares and
 equivalents outstanding........................   17,197     18,196    17,222    18,265

Additional  dilutive  shares using  ending  
 period  market value versus  average  market 
 value for the period when utilizing the
 treasury stock method regarding stock options..       16         34        71        68
                                                  -------    -------   -------   -------

Total shares for fully diluted earnings 
 per share......................................   17,213     18,230    17,293    18,333
                                                  =======    =======   =======   =======

Fully diluted earnings per share................    $ .81     $  .50    $ 1.40     $ .93
                                                  =======    =======   =======   =======
------------------
(1) Share and per share  information  have been  restated  to fully  reflect the 3-for-2 
    stock split effective January 23, 1997.
</TABLE>
# United States Court of Appeals

For the Seventh Circuit Chicago, Illinois 60604

Submitted April 21 , 2015 *

Decided April 22 , 2015

Before

WILLIAM J. BAUER

, Circuit Judge

DIANE S. SYKES

, Circuit Judge

JOHN DANIEL TINDER

, Circuit Judge

No. 14

- 3551 Appeal from the
United States District Court RICHARD GOODWIN,

P etitioner

- Appellant

,

v

.

UNITED STATES OF AMERICA, Respondent

- Appelle e

. for the Northern District of Illinois,
Eastern Division

.

No. 13 C 5038

Matthew F. Kennelly

, Judge

.

O R D E R

Richard Goo d win filed a motion under 28 U.S.C. § 2255 seeking to vacate his
sentence under the Armed Career Criminal Act

. 18 U.S.C. § 924(e)

. In 2003 a jury found
G oodwin guilty of possessing a firearm as a felon. See id. § 922(g)(1) . At sentencing the
district court pointed to t hree previous felony convictions and sentenced him as a career offe nder to 235 months’ imprisonment. See id. § 924(e)(1). Goodwin appealed

, and we
affirmed the conviction but remanded for the district court to consider only whether it would have imposed the same sentence in light of United States v. Booker , 543 U.S. 220

* After examining the briefs and record, we have concluded that oral argument is

unnecessary. Thus

, the appeal is submitted on the brief s and record. See F ED

. R. A PP

. P. 34(a)(2) (C)

. NONPRECEDENTIAL DISPOSITION To be cited only in accordance with Fed. R. App. P. 32.1No. 14

- 3551 Page 2

( 2005). The district court said on remand that it would have imposed the same sentence

, and we affirmed. United States v. Goodwin , 173 F. App’x 506 (7th Cir. 2006)

.

In 2013 Goodwin filed a motion under § 2255 asserting violations of his Fifth and
Sixth Ame ndment rights when the court relied on the t hree prior felony convictions to

sentence him as a career offender without having a jury find the fact of the convictions beyond a reasonable doubt

. See Alleyne v. United States , 133 S. Ct. 2151 (2013). The district

court denied his motion , concluding that under Almendarez

- Torres v. United States

, felon ies that form the basis for a § 924(e)(1) sentence enhancement need not be found by a jury. 523 U.S. 224 (1998). A few days later the judge issued a certificate of appealability.

On appeal Goodwin concedes that Almendarez

- Torres forecloses his argument, and so he seeks merely to preserve the issue for review in the Supreme Court. We have

many times stated that the rule announced in Almendarez

- Torres was not changed by Alleyne and remains good law. S ee United States v. Long , 748 F.3d 322, 329 (7th Cir. 2014); United States v. Johnson , 743 F.3d 1110, 1111 ( 7th Cir. 2014); United States v. Boyce , 742 F.3d 792, 799 (7th Cir. 2014 )

. We a re bound by Almendarez

- Torres and leave to the Supreme
Court whether to revisit that decision.

AFFIRMED.
EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Report of TrackPower, Inc. (the "Registrant") on Form
10-QSB for the period ended August 31, 2005 (the "Report") as filed with the
Securities and Exchange Commission on the date hereof, each of the undersigned,
in the capacities and on the dates indicated below, I, Edward M. Tracy, hereby
certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

1.    The Report fully complies with the requirements of Section 13(a) or 15(d)
      of the Securities Exchange Act of 1934; and

2.    The information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operation of the Company.


/s/ Edward M. Tracy
------------------------------------
Edward M. Tracy
Chairman and Chief Executive Officer
Dated: October 21, 2005
```

[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. Res. 281 Introduced in Senate (IS)]

111th CONGRESS
  1st Session
S. RES. 281

 Supporting the goals and ideals of ``National Campus Safety Awareness 
                                Month''.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                           September 23, 2009

   Mr. Specter (for himself and Mr. Durbin) submitted the following 
    resolution; which was referred to the Committee on the Judiciary

_______________________________________________________________________

                               RESOLUTION

 
 Supporting the goals and ideals of ``National Campus Safety Awareness 
                                Month''.

Whereas people on college and university campuses are not immune from the 
        potential acts of crime that the rest of society in the United States 
        faces;
Whereas, pursuant to the Jeanne Clery Disclosure of Campus Security Policy and 
        Campus Crime Statistics Act (20 U.S.C. 1092(f)), colleges and 
        universities reported that from 2005 to 2007, 117 murders, 10,563 
        forcible-sex offenses, 16,632 aggravated assaults, and 3,226 cases of 
        arson occurred on or around college and university campuses;
Whereas criminal experts estimate that between 20 to 25 percent of female 
        undergraduate students become victims of rape or attempted rape;
Whereas the aggressor in a sexual assault is usually an acquaintance or friend 
        of the victim;
Whereas less than 5 percent of the victims of sexual assaults report those 
        assaults to law enforcement;
Whereas each year 13 percent of female students enrolled in an undergraduate 
        program at a college or university will be victims of stalking;
Whereas approximately 1,825 college and university students between the ages of 
        18 and 24 die each year from unintentional, alcohol-related injuries, 
        including motor vehicle accidents;
Whereas Security On Campus, Inc., a national nonprofit group dedicated to 
        promoting safety and security on college and university campuses, has 
        designated September as National Campus Safety Awareness Month;
Whereas, each September since 2005, Security On Campus, Inc. has partnered with 
        colleges and universities across the United States to offer educational 
        programming on sexual assault, alcohol and drug abuse, hazing, stalking, 
        and other critical campus safety issues; and
Whereas National Campus Safety Awareness Month provides an opportunity for 
        campus communities to become engaged in efforts to improve campus 
        safety: Now, therefore, be it
    Resolved, That the Senate--
            (1) supports the goals and ideals of National Campus Safety 
        Awareness Month; and
            (2) encourages colleges and universities throughout the 
        United States to provide campus safety and other crime 
        awareness and prevention programs to students throughout the 
        year.
                                 <all>
```
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 96-6036

BARRY ALEXANDER ROBINSON,

Petitioner - Appellant,

versus

COMMONWEALTH OF VIRGINIA,

Respondent - Appellee.

Appeal from the United States District Court for the Eastern District of Virginia, at Richmond. David G. Lowe, Magistrate Judge.

(CA-95-771-3)

Submitted: March 21, 1996 Decided: April 16, 1996

Before NIEMEYER and MICHAEL, Circuit Judges, and BUTZNER, Senior

Circuit Judge.

Dismissed by unpublished per curiam opinion.

Barry Alexander Robinson, Appellant Pro Se. Thomas Drummond

Bagwell, Assistant Attorney General, Richmond, Virginia, for

Appellee.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
2

PER CURIAM:

Appellant seeks to appeal the magistrate judge's order denying

relief on his 28 U.S.C. § 2254 (1988) petition. We have reviewed

the record and the magistrate judge's opinion and find no reversible error. Accordingly, we deny a certificate of probable cause

to appeal and dismiss the appeal on the reasoning of the district

court. Robinson v. Virginia, No. CA-95-771-3 (E.D. Va. Dec. 19,

1995). We dispense with oral argument because the facts and legal

contentions are adequately presented in the materials before the

court and argument would not aid the decisional process.

DISMISSED
<PAGE>

                                                                     Exhibit 24


                                POWER OF ATTORNEY



         The undersigned, directors of The Raymond Corporation ("Corporation"),
hereby constitute and appoint Paul J. Sternberg and William B. Lynn, or either
of them, their respective true and lawful attorneys and agents, each with full
power and authority to act as such without the other, to sign the name of the
undersigned to the Corporation's fiscal 1996 Annual Report on Form 10-K, and to
any amendment thereto, to be filed with the Securities and Exchange Commission
under the Securities Exchange Act of 1934 and the related rules and regulations
thereunder, the undersigned hereby ratifying and confirming all that said
attorneys and agents, of either one of them, shall do or cause to be done by
virtue hereof.

         IN WITNESS WHEREOF, the undersigned have signed and delivered these
presents as of this 1st day of March, 1997.



/s/ Ross K. Colquhoun
--------------------------------------        ---------------------------------
Ross K. Colquhoun,                            George G. Raymond, Jr.,
Chairman of the Board, Chief Executive        Director
Officer and Director


/s/ James J. Malvaso                          /s/ Arthur M. Richardson
--------------------------------------        ---------------------------------
James J. Malvaso  .                           Arthur M. Richardson, Director
President, Chief Operating Officer
and Director


/s/ James F. Matthews                         /s/ Dr. M. Richard Rose
--------------------------------------        ---------------------------------
James F. Matthews, Director                   Dr. M. Richard Rose, Director


/s/ John E. Mott                              /s/ John V. Sponyoe
--------------------------------------        ---------------------------------
John E. Mott, Director                        John V. Sponyoe, Director


/s/ Michael R. Porter                         /s/ Michael O. Womack
--------------------------------------        ---------------------------------
Michael R. Porter, Director                   Michael O. Womack, Director
EX-10.16





 Exhibit 10.16 

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as
private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

AMENDMENT NO. 1 TO LICENSE AGREEMENT 

This Amendment No. 1 to License Agreement (this “Amendment”) is made and entered into as of February 2, 2016 (the “Amendment
Date”), and amends that certain License Agreement, dated as of July 16, 2014, as amended or supplemented through the Amendment Date (the “License Agreement”), by and between Caribou Biosciences, Inc. (“Caribou”) and
Intellia Therapeutics, Inc. (“Intellia”) (as successor in interest to Intellia, LLC under the License Agreement). Each of Caribou and Intellia may be referred to herein as a “Party” or together as “Parties.” Capitalized
terms not otherwise defined herein shall have the meanings ascribed to such terms in the License Agreement. 
 WHEREAS, Section 8.14 of the
License Agreement provides that the License Agreement may be amended, supplemented, or otherwise modified only by means of a written instrument signed by both Caribou and Intellia;  

[***] 
 WHEREAS [***] the Parties desire to amend the
License Agreement as more specifically set forth in this Amendment; 
 NOW THEREFORE, in consideration of the mutual covenants contained herein and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows to be effective as of the Amendment Date: 

1. Exhibit C of the License Agreement is hereby amended to delete all of the text before: 

“As set forth in further detail in the UC/Vienna License”:. 

2. Section 2.7(b)(i) of the License Agreement is hereby amended by adding the following at the end of such Section: 

“Furthermore, in consideration for Intellia’s rights granted herein [***], Intellia will owe to Caribou a royalty [***] on Net Sales
[***] of Products [***] in the Intellia Field. [***]” 
 3. To the extent not expressly amended by this Amendment, the
License Agreement, as amended, remains in full force and effect. [***] 
 4. This Amendment may be executed in one or more
counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. Facsimile or PDF execution and delivery of this Amendment by either Party will constitute a legal, valid and binding
execution and delivery of this Amendment by such Party. 












 IN WITNESS WHEREOF, the Parties hereto have duly executed and delivered this Amendment No. 1 to
License Agreement as of the Amendment Date.  
  

			
	CARIBOU BIOSCIENCES, INC.
		
	By:	 	 /s/ Rachel E. Haurwitz

	Rachel E. Haurwitz, Ph.D
	President & CEO
	
	INTELLIA THERAPEUTICS, INC.
		
	By:	 	 /s/ Nessan Bermingham

	Nessan Bermingham, Ph.D
	President & CEO
[Federal Register Volume 62, Number 60 (Friday, March 28, 1997)]
[Notices]
[Page 14885]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-7897]


-----------------------------------------------------------------------


COMMISSION ON CIVIL RIGHTS

Agenda and Notice of Public Meeting of the Washington Advisory 
Committee

    Notice is hereby given, pursuant to the provisions of the rules and 
regulations of the U.S. Commission on Civil Rights, that a meeting of 
the Washington Advisory Committee to the Commission will convene at 
9:30 a.m. and adjourn at 12:00 p.m., on April 23, 1997, at the Westin 
Hotel, 1900 Fifth Street, Seattle, Washington 98101. The purpose of the 
meeting is to discuss on-going civil rights concerns and welfare reform 
monitoring.
    Persons desiring additional information, or planning a presentation 
to the Committee, should contact Committee Chairperson William 
Wassmuth, 206-233-0611, or Philip Montez, Director of the Western 
Regional Office, 213-894-3437 (TDD 213-894-3435). Hearing-impaired 
persons who will attend the meeting and require the services of a sign 
language interpreter should contact the Regional Office at least five 
(5) working days before the scheduled date of the meeting.
    The meeting will be conducted pursuant to the provisions of the 
rules and regulations of the Commission.

    Dated at Washington, DC, March 20, 1997.
Carol-Lee Hurley,
Chief, Regional Programs Coordination Unit.
[FR Doc. 97-7897 Filed 3-27-97; 8:45 am]
BILLING CODE 6335-01-P
[Federal Register Volume 62, Number 64 (Thursday, April 3, 1997)]
[Notices]
[Page 15945]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-8652]


-----------------------------------------------------------------------


SECURITIES AND EXCHANGE COMMISSION

Sunshine Act Meetings

    Notice is hereby given, pursuant to the provisions of the 
Government in the Sunshine Act, Pub. L. 94-409, that the Securities and 
Exchange Commission will hold the following meetings during the week of 
April 7, 1997.
    An open meeting will be held on Tuesday, April 8, 1997, at 10:00 
a.m. A closed meeting will be held on Wednesday, April 9, 1997, at 
10:00 a.m.
    Commissioners, Counsel to the Commissioners, the Secretary to the 
Commission, and recording secretaries will attend the closed meeting. 
Certain staff members who have an interest in the matters may also be 
present.
    The General Counsel of the Commission, or his designee, has 
certified that, in his opinion, one or more of the exemptions set forth 
in 5 U.S.C. 552b(c) (4), (8), (9)(A) and (10) and 17 CFR 200.402(a) 
(4), (8), (9)(i) and (10), permit consideration of the scheduled 
matters at the closed meeting.
    Commissioner Hunt, as duty officer, voted to consider the items 
listed for the closed meeting in a closed session.
    The subject matter of the open meeting scheduled for Tuesday, April 
8, 1997, at 10:00 a.m., will be:

    The Commission will meet with representatives from the American 
Society of Corporate Secretaries to discuss a number of issues of 
mutual interest, including the Plain English pilot program and 
proposing release, EDGAR and electronic dissemination of information 
to shareholders, the shareholder proposal rules, Rule 144, direct 
shareholder communications, direct registration and direct purchase 
plans, and lost securities holders. For further information, please 
contact Marija Willen at (202) 942-2840.

    The subject matter of the closed meeting scheduled for Wednesday, 
April 9, 1997, at 10:00 a.m., will be:

    Institution of injunctive actions.
    Institution and settlement of administrative proceedings of an 
enforcement nature.

    At times, changes in Commission priorities require alternations in 
the scheduling of meeting items. For further information and to 
ascertain what, if any, matters have been added, deleted or postponed, 
please contact: The Office of the Secretary at (202) 942-7070.

    Dated: April 1, 1997.
Jonathan G. Katz,
Secretary.
[FR Doc. 97-8652 Filed 4-1-97; 2:41 am]
BILLING CODE 8010-01-M
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF MEDICAL INCOME PROPERTIES 2B LIMITED PARTNERSHIP FOR THE
QUARTER ENDED MARCH 31, 1998, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                         970,606
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             1,000,570
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              11,340,355
<CURRENT-LIABILITIES>                        9,963,819
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   1,376,516<F1>
<TOTAL-LIABILITY-AND-EQUITY>                11,340,355
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                               (12,994)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  3,040
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                 (16,201)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    13,161
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
<FN>
<F1>REPRESENT TOTAL PARTNERSHIP CAPITAL INCLUDING NET INCOME NET OF 
DISTRIBUTIONS.
</FN>
        

</TABLE>